WORLD-CLASS NEW TECHNOLOGIES IN THE TREATMENT OF URINARY DISEASES
Keywords:
Diagnostic tools, future technology, imaging, roboticsAbstract
Since prehistoric times, our understanding of urology has rapidly expanded. Whilst primitive urologists began by using urine as a therapeutic substance, modern urologists may find themselves removing a kidney remotely by driving a robotic arm, with seven degrees of movement, while using image overlay-augmented reality. This review provides an insight into the potential status of urological technology in 20 years’ time, assessed through an analysis of developments in imaging, diagnostics, robotics and further technologies. A particular emphasis is given to the promising fields of minimally invasive techniques, nanotechnology and tissue engineering, which likely hold the key to a new era for urology
References
Nahon I, Waddington G, Dorey G, et al. The history of urologic surgery: from reeds to robotics. Urol Nurs 2011; 31: 173–180. [PubMed] [Google Scholar]
Venkatramani V. Urovision 2020: the future of urology. Indian J Urol 2015; 31: 150–155. [PMC free article] [PubMed] [Google Scholar]
Gono K, Obi T, Yamaguchi M, et al. Appearance of enhanced tissue features in narrow-band endoscopic imaging. J Biomed Opt 2004; 9: 568–577. [PubMed] [Google Scholar]
Hsueh TY, Chiu AW. Narrow band imaging for bladder cancer. Asian J Urol 2016; 3: 126–129. [PMC free article] [PubMed] [Google Scholar]
Jin S, Labhasetwar V. Nanotechnology in urology. Urol Clin North Am 2009; 36: 179–188, viii. [PMC free article] [PubMed] [Google Scholar]
Dickinson L, Ahmed HU, Hindley RG, et al. Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity-focused ultrasound focal therapy for localized prostate cancer. Urol Oncol 2017; 35: 30.e9–.e15. [PubMed] [Google Scholar]
Marks L, Young S, Natarajan S. MRI-ultrasound fusion for guidance of targeted prostate biopsy. Curr Opin Urol 2013; 23: 43–50. [PMC free article] [PubMed] [Google Scholar]
Kamrava M, Kishan AU, Margolis DJ, et al. Multiparametric magnetic resonance imaging for prostate cancer improves Gleason score assessment in favorable risk prostate cancer. Pract Radiat Oncol 2015; 5: 411–416. [PMC free article] [PubMed] [Google Scholar]
Erturk MA, Raaijmakers AJE, Adriany G, et al. A 16-channel combined loop-dipole transceiver array for 7 Tesla body MRI. Magn Reson Med 2017; 77: 884–894. [PMC free article] [PubMed] [Google Scholar]
Gauthe M, Belissant O, Yin JZ, et al. Use of Ga-68-PSMA-11 PET/CT when F-18-fluorocholine cannot localize biological recurrence of prostate cancer: report of a case and review of the literature. Med Nucl 2017; 41: 453–457. [Google Scholar]
Pouliot F, Bauman G, Chua S, et al. A prospective multicenter study comparing multi-parametric magnetic resonance imaging (MP-MRI), F-18 fluoro-methyl-choline (FCH) and GA-68 GBED-CC-(PSMA) positron emission tomography in patients being considered for salvage radiation therapy for biochemical failure after radical prostatectomy. J Urology 2018; 199: E731-E. [Google Scholar]
Perera M, Papa N, Christidis D, et al. Sensitivity, specificity, and predictors of positive Ga-68-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 2016; 70: 926–937. [PubMed] [Google Scholar]
Hofman MS, Murphy DG, Williams SG, et al. A prospective randomised multi-centre study of the impact of Ga-68 PSMA-PET/CT imaging for staging high risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol. BJU Int. Epub ahead of print 3 May 2018. DOI: 10.1111/bju.14374. [PubMed] [CrossRef] [Google Scholar]
Mehawed G, Choi W, Joshi A, et al. Initial experience of novel hybrid PSMA PET/MRI imaging for lymph node staging in prostate cancer. J Urol 2018; 199: E527-E. [Google Scholar]
Joshi A, Rhee H, Pryor D, et al. The clinical efficacy of PSMA PET/MRI in biochemically recurrent prostate cancer compared with standard of care imaging modalities – results of a multi-centre, prospective clinical trial. J Urol 2018; 199: E731-E. [Google Scholar]
Demirkol MO, Kiremit MC, Acar O, et al. Local salvage treatment of post-brachytherapy recurrent prostate cancer via theranostic application of PSMA-labeled lutetium-177. Clin Genitourin Cancer 2018; 16: 99–102. [PubMed] [Google Scholar]
Hofman MS, Violet J, Hicks RJ, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol 2018; pii: S1470-2045(18)30198-0. [PubMed] [Google Scholar]
Vogelzang NJ, Fizazi K, Burke JM, et al. Circulating tumor cells in a phase 3 study of docetaxel and prednisone with or without lenalidomide in metastatic castration-resistant prostate cancer. Eur Urol 2017; 71: 168–171. [PubMed] [Google Scholar]
Ashworth T. A case of cancer in which cells similar to those in the tumors were seen in blood after death. Aust Med J 1869; 14: 146–147. [Google Scholar]
Flaig TW, Wilson S, van Bokhoven A, et al. Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma. Urology 2011; 78: 863–867. [PMC free article] [PubMed] [Google Scholar]
Albers P, Albrecht W, Algaba F, et al. Guidelines on testicular cancer: 2015 update. Eur Urol 2015; 68: 1054–1068. [PubMed] [Google Scholar]
Dieckmann KP, Radtke A, Spiekermann M, et al. Serum levels of MicroRNA miR-371a-3p: a sensitive and specific new biomarker for germ cell tumours. Eur Urol 2017; 71: 213–220. [PubMed] [Google Scholar]
Taverna G, Tidu L, Grizzi F, et al. Olfactory system of highly trained dogs detects prostate cancer in urine samples. J Urol 2015; 193: 1382–1387. [PubMed] [Google Scholar]
Ramirez D, Maurice MJ, Kaouk JH. Robotic single-port surgery: paving the way for the future. Urology 2016; 95: 5–10. [PubMed] [Google Scholar]
Kaouk JH, Haber GP, Autorino R, et al. A novel robotic system for single-port urologic surgery: first clinical investigation. Eur Urol 2014; 66: 1033–1043. [PubMed] [Google Scholar]
Comella LM, Ayvazov K, Cuntz T, et al. Characterization of a capacitive position sensor for a miniaturized hydraulic actuator. IEEE Sensors Journal 2017; 17: 113–120. [Google Scholar]
Cornejo-Davila V, Nazmy M, Jr, Kella, et al. Use of near infrared fluorescence during robot-assisted laparoscopic partial nephrectomy. Actas Urol Esp 2016; 40: 190–194. [PubMed] [Google Scholar]
Ramirez D, Zargar H, Caputo P, et al. Robotic-assisted laparoscopic prostatectomy: an update on functional and oncologic outcomes, techniques, and advancements in technology. J Surg Oncol 2015; 112: 746–752. [PubMed] [Google Scholar]
Akca O, Zargar H, Kaouk JH. Robotic surgery revives radical perineal prostatectomy. Eur Urol 2015; 68: 340–341. [PubMed] [Google Scholar]
Bach T, Muschter R, Herrmann TRW, et al. Technical solutions to improve the management of non-muscle-invasive transitional cell carcinoma: summary of a European Association of Urology Section for Uro-Technology (ESUT) and Section for Uro-Oncology (ESOU) expert meeting and current and future perspectives. BJU Int 2015; 115: 14–23. [PubMed] [Google Scholar]
Rassweiler JJ, Autorino R, Klein J, et al. Future of robotic surgery in urology. BJU Int 2017; 120: 822–841. [PubMed] [Google Scholar]
Warren H, Dasgupta P. The future of robotics. Investig Clin Urol 2017; 58: 297–298. [PMC free article] [PubMed] [Google Scholar]
Srougi V, Yorioka M, Sanchez DC, et al. The feasibility of robotic urologic surgery in infants and toddlers. J Pediatr Urol 2013; 9(6 Pt B): 1198–1203. [PubMed] [Google Scholar]
Miniati R, Dori F, Frosini F, et al. Integrated HTA and FMECA methodology for the evaluation of robotic surgery. In: Kyriacou E, Christofides S, Pattichis CS. (eds) XIV Mediterranean Conference on Medical and Biological Engineering and Computing 2016 Vol. 57 IFMBE Proceedings 2016, pp. 1004–1007, Springer International Publishing. [Google Scholar]
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
